PR
    Pharmacy Remedy

    Ocrevus (Ocrelizumab)

    Ocrevus (ocrelizumab) · anti-CD20 monoclonal antibody for multiple sclerosis · Roche

    Ocrevus (ocrelizumab) is a humanised anti-CD20 monoclonal antibody manufactured by Roche, approved for relapsing forms of multiple sclerosis and for primary progressive multiple sclerosis. It depletes CD20-positive B lymphocytes and is given by intravenous infusion approximately every six months, requiring continuous 2–8 °C cold-chain storage.

    Prescription-only medicine. No pricing is published on this page. Pharmacy Remedy provides pharmaceutical sourcing and procurement support in Türkiye and does not sell medicines to the public.

    This page is informational and is not an advertisement or medical advice. Treatment decisions belong to your treating physician.

    What it is and what it treats

    Ocrevus (ocrelizumab) is a humanised monoclonal antibody that selectively targets CD20-expressing B lymphocytes, a cell population implicated in the inflammatory and neurodegenerative processes underlying multiple sclerosis (MS).

    It is approved for the treatment of relapsing forms of multiple sclerosis and, notably, for primary progressive multiple sclerosis (PPMS), a form of the disease for which few disease-modifying options exist. Regulatory approval for the PPMS indication was based on the ORATORIO trial, which described a reduction in confirmed disability progression relative to placebo.

    In relapsing MS, Phase III trials comparing ocrelizumab with interferon beta-1a described reductions in annualised relapse rates and MRI lesion activity, supporting its role as a disease-modifying therapy for patients with active relapsing disease as determined by a treating neurologist.

    Presentations and dosage forms

    • Concentrate for solution for infusion, 300 mg per 10 mL vial
    • Administered following dilution, by intravenous infusion only
    • No subcutaneous, oral or self-administered presentation is authorised

    How it is administered

    The EU SmPC describes an initial dosing regimen of 300 mg administered by intravenous infusion, followed by a second 300 mg infusion two weeks later. Subsequent doses are described as 600 mg administered by intravenous infusion once every six months.

    Each infusion is administered over an extended period with a defined starting rate that may be increased if tolerated, and premedication with a corticosteroid and an antihistamine is described in the label to reduce the frequency and severity of infusion-related reactions.

    Administration takes place in a healthcare setting equipped to manage infusion reactions and with access to management of hypersensitivity. The label describes screening for hepatitis B and other relevant precautions prior to initiating treatment, along with ongoing clinical monitoring.

    Storage and handling

    • Store at 2–8 °C under continuous refrigeration; do not freeze
    • Keep the vial in the outer carton to protect from light
    • Do not shake the vial
    • Diluted infusion solution should be used within the timeframe described in the SmPC
    • Cold-chain integrity must be maintained throughout transport and storage

    Side effects

    The following reflects the adverse reaction profile described in the approved EU SmPC for ocrelizumab.

    Commonly reported

    • Infusion-related reactions
    • Upper respiratory tract infections
    • Nasopharyngitis
    • Skin infections
    • Cough
    • Lower respiratory tract infections

    Serious effects requiring medical attention

    • Serious infections, including reactivation of hepatitis B
    • Progressive multifocal leukoencephalopathy (PML), reported rarely
    • Severe infusion reactions including hypersensitivity
    • Reduced immunoglobulin levels with prolonged use, which may increase infection risk

    Patients should seek prompt medical attention for signs of infection, new neurological symptoms, or reactions during or after infusion; suspected adverse reactions should be reported through the relevant national pharmacovigilance scheme.

    Ocrevus compared with other multiple sclerosis therapies

    Ocrevus is distinguished from other B-cell-depleting or immune-modulating MS therapies, such as ofatumumab (a self-administered subcutaneous anti-CD20 antibody dosed monthly) and natalizumab (an alpha-4 integrin inhibitor dosed every four weeks), by its twice-yearly intravenous infusion schedule and its additional approval for primary progressive disease.

    Selection among disease-modifying therapies for MS depends on disease subtype, activity, prior treatment history and individual risk factors, and should be made by a neurologist experienced in MS management rather than by direct comparison of dosing convenience alone.

    Availability and supply route

    Marketing authorisation status for Ocrevus varies by country, and approved indications, dosing schedules and pack presentations may differ between the EU, US and other regulated markets. Institutions should confirm local registration status before planning treatment.

    Where local registration or supply is limited, named-patient or specials import frameworks exist in many jurisdictions to permit supply of a foreign-registered medicine against a valid prescription and appropriate regulatory documentation, under the responsibility of the treating physician.

    Pharmacy Remedy is a licensed Turkish pharmaceutical wholesaler that supplies medicines through licensed distribution channels to hospitals, pharmacies and other authorised institutions; it does not sell medicines directly to the public and all supply is conditional on valid prescriptions and applicable import documentation.

    Why the same medicine is priced differently in Türkiye

    This is how the Turkish pricing system works. These are published facts about a state mechanism, not a claim about what we charge.

    • Turkish medicine prices are calculated from a fixed pharmaceutical euro rate rather than the spot exchange rate. Under Decision No. 11031 (Resmî Gazete 33194, 12 March 2026) that rate is set at 65% of the previous year's average Turkish Central Bank euro selling rate.
    • The reference price is derived from the lowest ex-factory price in a basket of five to ten EU member states designated by the Ministry of Health.
    • A mandatory public discount of roughly 28–41% is then applied, depending on the product category and price band. The band thresholds change with each SUT revision, so we do not reproduce them here.
    • The pharmaceutical euro rate in force since 1 April 2026 is 29.1164 TL.

    Official published lists — our figures appear nowhere

    We publish no price. Each authority below publishes its own list. Read them directly:

    Compare them yourself.

    For international context: RAND Corporation, analysing 2022 data and publishing in February 2024, found US prices were 278% of prices in 33 other high-income countries, rising to 422% for brand-name originator medicines.

    How to obtain a price

    We do not publish prices. The price depends on the dose, the number of vials and the number of treatment cycles. Send your prescription and medical report and you will receive a written quote within 24 hours.

    Sourced through Türkiye pharmacy channels · İTS serial-traceable — every Turkish pack carries an İTS karekod encoding the GTIN, serial number, batch and expiry, which can be checked against Türkiye's Pharmaceutical Track and Trace System.

    How to obtain a price

    Frequently asked questions

    What is Ocrevus used for?

    Ocrevus (ocrelizumab) is used to treat relapsing forms of multiple sclerosis and primary progressive multiple sclerosis.

    How often is Ocrevus given?

    Following an initial two-dose loading regimen, Ocrevus is given by intravenous infusion approximately once every six months per the approved label.

    Does Ocrevus require refrigeration?

    Yes. Ocrevus must be stored at 2–8 °C at all times, including during transport, and must not be frozen.

    Is Ocrevus approved for primary progressive MS?

    Yes. Ocrevus is approved for PPMS based on clinical trial data describing reduced disability progression compared with placebo, one of few disease-modifying options for this MS subtype.

    What precautions are needed before starting Ocrevus?

    The label describes hepatitis B screening and premedication with a corticosteroid and antihistamine prior to infusions to reduce infusion-related reactions.

    What are the serious risks associated with Ocrevus?

    Serious infections, hepatitis B reactivation and rare cases of progressive multifocal leukoencephalopathy have been described, requiring ongoing clinical monitoring.

    Can Pharmacy Remedy supply Ocrevus directly to patients?

    No. Pharmacy Remedy is a licensed wholesaler supplying hospitals, pharmacies and authorised institutions through valid prescriptions and import documentation; it does not sell to the public.

    Primary sources

    Further reading and regulatory routes

    Related medicines

    Prescription-based enquiry

    If you hold a valid prescription from a treating physician, send us the prescription details and we will reply with the regulatory and documentation position for that specific product. We do not publish pricing and we do not sell to the public.

    Send a prescription-based enquiry

    Reviewed by Pharmacy Remedy Pharmacovigilance & Compliance Desk · Last updated: 2026-07-30

    For healthcare professionals

    Prescribers, hospital and specialty pharmacies, oncology centres and procurement departments: named patient supply, documentation and the sourcing workflow.